Global Metformin Drugs Market
Global Metformin Drugs Market

Metformin Drugs Comprehensive Study by Type (Metformin-Alogliptin, Metformin-Canagliflozin, Metformin-Dapagliflozin, Metformin-Empagliflozin, Others), Category (Immediate Release, Extended Release), Form (Tablets, Capsules, Liquid), Distribution Channel (Retail Pharmacies, Hospitals Dispensaries, Third Party Websites) Players and Region - Global Market Outlook to 2026

Metformin Drugs Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

May 2021 Edition 211 Pages 217 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Metformin Drugs Market Overview:
Metformin is the most often used oral hypoglycemic agent today. This article discusses how it should be used to cure type 2 diabetes. The major mechanisms of action include decreased appetite and carbohydrate absorption in the intestine, suppression of hepatic gluconeogenesis, and enhanced glucose uptake by peripheral tissues. Metformin has long been recognized as the first-line therapy for type 2 diabetes. Metformin's potency is matched by excellent safety: the medication can only be avoided in patients with apparent contraindications (mainly chronic renal failure, congestive heart failure, chronic obstructive pulmonary disease, liver disease). Furthermore, metformin's cost-effectiveness has been identified. In general, metformin is an ideal alternative for both specialist and primary care settings.

Growth Drivers
  • Increasing Affordability of Metformin Drugs
  • Prevalence of Type 2 Diabetic Conditions
  • Rising Geriatric Population

Market Trends
  • Technical Progress in Pharmaceutical Industry

Roadblocks
  • Lack of Trained Professionals
  • Limited Administrative Forms

Opportunities
  • Growing Healthcare Infrastructure

Challenges
  • Regulatory Approval
  • High Initial Investment


Competitive Landscape:
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Bristol-Mayers Squibb (United States), Teva Pharmaceutical Industries Ltd. (Israel), Harman Finochem (India), Vistin Pharma (Norway), China Res Double-Crane (China), Farmhispania Group (Spain), Shijiazhuang Polee Pharmaceutical (China), Merck Sante S.A.S. (France), Aarti Drugs Limited (India) and Taj Pharmaceuticals Limited (India). Additionally, following companies can also be profiled that are part of our coverage like Wanbury Limited (India), Granules India Limited (India), Keyuan Pharmaceutical (China) and Fukang Pharmaceutical (China). Analyst at AMA Research see Indian & Chinese Players to retain maximum share of Global Metformin Drugs market by 2026. Considering Market by Category, the sub-segment i.e. Immediate Release will boost the Metformin Drugs market. Considering Market by Form, the sub-segment i.e. Tablets will boost the Metformin Drugs market. Considering Market by Distribution Channel, the sub-segment i.e. Retail Pharmacies will boost the Metformin Drugs market.

Latest Market Insights:
On 16th December, 2019 – Cipla Acquired Brand Name and Trademark Rights for its Vysov For Anti-Diabetic Drug Vildagliptin For the Indian Market from Novartis AG. Before the Acquisition Cipla Co-Marketed Under Brand Names Vysov and Vysov M (Vildagliptin plus Metformin).

On 26th February, 2020 - Sun Pharma Launched RIOMET ER Oral Suspension (Metformin Hydrochloride for Extended-Release Oral Suspension), The Only U.S. FDA-Approved Extended-Release Liquid Formulation of Metformin for Adults that are Unable to Swallow Solid Medication Types. and On 13th January, 2021 - Granules India Received USFDA Approval of its Abbreviated New Drug Application (ANDA) Metformin Hydrochloride ER Tablets. Metformin Tablets are Recommended as An Adjunct to Diet and Exercise in Adults with Type 2 Diabetes Mellitus to Enhance Glycemic Control.

United States, Food and Drug Administration “Metformin Label” - Provides a Comprehensive List of Procedures Regarding the Usage, Indications and Dosage Requirements of Metformin Drugs Based on the Patient Profile. Any New Entrant is Required to have Regulatory FDA Approval for Sale Across US.

What Can be Explored with the Metformin Drugs Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Metformin Drugs Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Metformin Drugs
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Metformin Drugs market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Metformin Drugs market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Metformin Drugs Manufactures, New Entrants and Investors, API Providers, Metformin Drugs Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • Metformin-Alogliptin
  • Metformin-Canagliflozin
  • Metformin-Dapagliflozin
  • Metformin-Empagliflozin
  • Others
By Category
  • Immediate Release
  • Extended Release

By Form
  • Tablets
  • Capsules
  • Liquid

By Distribution Channel
  • Retail Pharmacies
  • Hospitals Dispensaries
  • Third Party Websites

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Affordability of Metformin Drugs
      • 3.2.2. Prevalence of Type 2 Diabetic Conditions
      • 3.2.3. Rising Geriatric Population
    • 3.3. Market Challenges
      • 3.3.1. Regulatory Approval
      • 3.3.2. High Initial Investment
    • 3.4. Market Trends
      • 3.4.1. Technical Progress in Pharmaceutical Industry
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Metformin Drugs, by Type, Category, Form, Distribution Channel and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Metformin Drugs (Value)
      • 5.2.1. Global Metformin Drugs by: Type (Value)
        • 5.2.1.1. Metformin-Alogliptin
        • 5.2.1.2. Metformin-Canagliflozin
        • 5.2.1.3. Metformin-Dapagliflozin
        • 5.2.1.4. Metformin-Empagliflozin
        • 5.2.1.5. Others
      • 5.2.2. Global Metformin Drugs by: Category (Value)
        • 5.2.2.1. Immediate Release
        • 5.2.2.2. Extended Release
      • 5.2.3. Global Metformin Drugs by: Form (Value)
        • 5.2.3.1. Tablets
        • 5.2.3.2. Capsules
        • 5.2.3.3. Liquid
      • 5.2.4. Global Metformin Drugs by: Distribution Channel (Value)
        • 5.2.4.1. Retail Pharmacies
        • 5.2.4.2. Hospitals Dispensaries
        • 5.2.4.3. Third Party Websites
      • 5.2.5. Global Metformin Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Metformin Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bristol-Mayers Squibb (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Harman Finochem (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Vistin Pharma (Norway)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. China Res Double-Crane (China)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Farmhispania Group (Spain)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Shijiazhuang Polee Pharmaceutical (China)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Merck Sante S.A.S. (France)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Aarti Drugs Limited (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Taj Pharmaceuticals Limited (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Metformin Drugs Sale, by Type, Category, Form, Distribution Channel and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Metformin Drugs (Value)
      • 7.2.1. Global Metformin Drugs by: Type (Value)
        • 7.2.1.1. Metformin-Alogliptin
        • 7.2.1.2. Metformin-Canagliflozin
        • 7.2.1.3. Metformin-Dapagliflozin
        • 7.2.1.4. Metformin-Empagliflozin
        • 7.2.1.5. Others
      • 7.2.2. Global Metformin Drugs by: Category (Value)
        • 7.2.2.1. Immediate Release
        • 7.2.2.2. Extended Release
      • 7.2.3. Global Metformin Drugs by: Form (Value)
        • 7.2.3.1. Tablets
        • 7.2.3.2. Capsules
        • 7.2.3.3. Liquid
      • 7.2.4. Global Metformin Drugs by: Distribution Channel (Value)
        • 7.2.4.1. Retail Pharmacies
        • 7.2.4.2. Hospitals Dispensaries
        • 7.2.4.3. Third Party Websites
      • 7.2.5. Global Metformin Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Metformin Drugs: by Type(USD Million)
  • Table 2. Metformin Drugs Metformin-Alogliptin , by Region USD Million (2015-2020)
  • Table 3. Metformin Drugs Metformin-Canagliflozin , by Region USD Million (2015-2020)
  • Table 4. Metformin Drugs Metformin-Dapagliflozin , by Region USD Million (2015-2020)
  • Table 5. Metformin Drugs Metformin-Empagliflozin , by Region USD Million (2015-2020)
  • Table 6. Metformin Drugs Others , by Region USD Million (2015-2020)
  • Table 7. Metformin Drugs: by Category(USD Million)
  • Table 8. Metformin Drugs Immediate Release , by Region USD Million (2015-2020)
  • Table 9. Metformin Drugs Extended Release , by Region USD Million (2015-2020)
  • Table 10. Metformin Drugs: by Form(USD Million)
  • Table 11. Metformin Drugs Tablets , by Region USD Million (2015-2020)
  • Table 12. Metformin Drugs Capsules , by Region USD Million (2015-2020)
  • Table 13. Metformin Drugs Liquid , by Region USD Million (2015-2020)
  • Table 14. Metformin Drugs: by Distribution Channel(USD Million)
  • Table 15. Metformin Drugs Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 16. Metformin Drugs Hospitals Dispensaries , by Region USD Million (2015-2020)
  • Table 17. Metformin Drugs Third Party Websites , by Region USD Million (2015-2020)
  • Table 18. South America Metformin Drugs, by Country USD Million (2015-2020)
  • Table 19. South America Metformin Drugs, by Type USD Million (2015-2020)
  • Table 20. South America Metformin Drugs, by Category USD Million (2015-2020)
  • Table 21. South America Metformin Drugs, by Form USD Million (2015-2020)
  • Table 22. South America Metformin Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 23. Brazil Metformin Drugs, by Type USD Million (2015-2020)
  • Table 24. Brazil Metformin Drugs, by Category USD Million (2015-2020)
  • Table 25. Brazil Metformin Drugs, by Form USD Million (2015-2020)
  • Table 26. Brazil Metformin Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 27. Argentina Metformin Drugs, by Type USD Million (2015-2020)
  • Table 28. Argentina Metformin Drugs, by Category USD Million (2015-2020)
  • Table 29. Argentina Metformin Drugs, by Form USD Million (2015-2020)
  • Table 30. Argentina Metformin Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 31. Rest of South America Metformin Drugs, by Type USD Million (2015-2020)
  • Table 32. Rest of South America Metformin Drugs, by Category USD Million (2015-2020)
  • Table 33. Rest of South America Metformin Drugs, by Form USD Million (2015-2020)
  • Table 34. Rest of South America Metformin Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 35. Asia Pacific Metformin Drugs, by Country USD Million (2015-2020)
  • Table 36. Asia Pacific Metformin Drugs, by Type USD Million (2015-2020)
  • Table 37. Asia Pacific Metformin Drugs, by Category USD Million (2015-2020)
  • Table 38. Asia Pacific Metformin Drugs, by Form USD Million (2015-2020)
  • Table 39. Asia Pacific Metformin Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 40. China Metformin Drugs, by Type USD Million (2015-2020)
  • Table 41. China Metformin Drugs, by Category USD Million (2015-2020)
  • Table 42. China Metformin Drugs, by Form USD Million (2015-2020)
  • Table 43. China Metformin Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 44. Japan Metformin Drugs, by Type USD Million (2015-2020)
  • Table 45. Japan Metformin Drugs, by Category USD Million (2015-2020)
  • Table 46. Japan Metformin Drugs, by Form USD Million (2015-2020)
  • Table 47. Japan Metformin Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 48. India Metformin Drugs, by Type USD Million (2015-2020)
  • Table 49. India Metformin Drugs, by Category USD Million (2015-2020)
  • Table 50. India Metformin Drugs, by Form USD Million (2015-2020)
  • Table 51. India Metformin Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 52. South Korea Metformin Drugs, by Type USD Million (2015-2020)
  • Table 53. South Korea Metformin Drugs, by Category USD Million (2015-2020)
  • Table 54. South Korea Metformin Drugs, by Form USD Million (2015-2020)
  • Table 55. South Korea Metformin Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 56. Taiwan Metformin Drugs, by Type USD Million (2015-2020)
  • Table 57. Taiwan Metformin Drugs, by Category USD Million (2015-2020)
  • Table 58. Taiwan Metformin Drugs, by Form USD Million (2015-2020)
  • Table 59. Taiwan Metformin Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 60. Australia Metformin Drugs, by Type USD Million (2015-2020)
  • Table 61. Australia Metformin Drugs, by Category USD Million (2015-2020)
  • Table 62. Australia Metformin Drugs, by Form USD Million (2015-2020)
  • Table 63. Australia Metformin Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific Metformin Drugs, by Type USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Metformin Drugs, by Category USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Metformin Drugs, by Form USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Metformin Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 68. Europe Metformin Drugs, by Country USD Million (2015-2020)
  • Table 69. Europe Metformin Drugs, by Type USD Million (2015-2020)
  • Table 70. Europe Metformin Drugs, by Category USD Million (2015-2020)
  • Table 71. Europe Metformin Drugs, by Form USD Million (2015-2020)
  • Table 72. Europe Metformin Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 73. Germany Metformin Drugs, by Type USD Million (2015-2020)
  • Table 74. Germany Metformin Drugs, by Category USD Million (2015-2020)
  • Table 75. Germany Metformin Drugs, by Form USD Million (2015-2020)
  • Table 76. Germany Metformin Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 77. France Metformin Drugs, by Type USD Million (2015-2020)
  • Table 78. France Metformin Drugs, by Category USD Million (2015-2020)
  • Table 79. France Metformin Drugs, by Form USD Million (2015-2020)
  • Table 80. France Metformin Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 81. Italy Metformin Drugs, by Type USD Million (2015-2020)
  • Table 82. Italy Metformin Drugs, by Category USD Million (2015-2020)
  • Table 83. Italy Metformin Drugs, by Form USD Million (2015-2020)
  • Table 84. Italy Metformin Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 85. United Kingdom Metformin Drugs, by Type USD Million (2015-2020)
  • Table 86. United Kingdom Metformin Drugs, by Category USD Million (2015-2020)
  • Table 87. United Kingdom Metformin Drugs, by Form USD Million (2015-2020)
  • Table 88. United Kingdom Metformin Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 89. Netherlands Metformin Drugs, by Type USD Million (2015-2020)
  • Table 90. Netherlands Metformin Drugs, by Category USD Million (2015-2020)
  • Table 91. Netherlands Metformin Drugs, by Form USD Million (2015-2020)
  • Table 92. Netherlands Metformin Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 93. Rest of Europe Metformin Drugs, by Type USD Million (2015-2020)
  • Table 94. Rest of Europe Metformin Drugs, by Category USD Million (2015-2020)
  • Table 95. Rest of Europe Metformin Drugs, by Form USD Million (2015-2020)
  • Table 96. Rest of Europe Metformin Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 97. MEA Metformin Drugs, by Country USD Million (2015-2020)
  • Table 98. MEA Metformin Drugs, by Type USD Million (2015-2020)
  • Table 99. MEA Metformin Drugs, by Category USD Million (2015-2020)
  • Table 100. MEA Metformin Drugs, by Form USD Million (2015-2020)
  • Table 101. MEA Metformin Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 102. Middle East Metformin Drugs, by Type USD Million (2015-2020)
  • Table 103. Middle East Metformin Drugs, by Category USD Million (2015-2020)
  • Table 104. Middle East Metformin Drugs, by Form USD Million (2015-2020)
  • Table 105. Middle East Metformin Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 106. Africa Metformin Drugs, by Type USD Million (2015-2020)
  • Table 107. Africa Metformin Drugs, by Category USD Million (2015-2020)
  • Table 108. Africa Metformin Drugs, by Form USD Million (2015-2020)
  • Table 109. Africa Metformin Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 110. North America Metformin Drugs, by Country USD Million (2015-2020)
  • Table 111. North America Metformin Drugs, by Type USD Million (2015-2020)
  • Table 112. North America Metformin Drugs, by Category USD Million (2015-2020)
  • Table 113. North America Metformin Drugs, by Form USD Million (2015-2020)
  • Table 114. North America Metformin Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 115. United States Metformin Drugs, by Type USD Million (2015-2020)
  • Table 116. United States Metformin Drugs, by Category USD Million (2015-2020)
  • Table 117. United States Metformin Drugs, by Form USD Million (2015-2020)
  • Table 118. United States Metformin Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 119. Canada Metformin Drugs, by Type USD Million (2015-2020)
  • Table 120. Canada Metformin Drugs, by Category USD Million (2015-2020)
  • Table 121. Canada Metformin Drugs, by Form USD Million (2015-2020)
  • Table 122. Canada Metformin Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 123. Mexico Metformin Drugs, by Type USD Million (2015-2020)
  • Table 124. Mexico Metformin Drugs, by Category USD Million (2015-2020)
  • Table 125. Mexico Metformin Drugs, by Form USD Million (2015-2020)
  • Table 126. Mexico Metformin Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Metformin Drugs: by Type(USD Million)
  • Table 138. Metformin Drugs Metformin-Alogliptin , by Region USD Million (2021-2026)
  • Table 139. Metformin Drugs Metformin-Canagliflozin , by Region USD Million (2021-2026)
  • Table 140. Metformin Drugs Metformin-Dapagliflozin , by Region USD Million (2021-2026)
  • Table 141. Metformin Drugs Metformin-Empagliflozin , by Region USD Million (2021-2026)
  • Table 142. Metformin Drugs Others , by Region USD Million (2021-2026)
  • Table 143. Metformin Drugs: by Category(USD Million)
  • Table 144. Metformin Drugs Immediate Release , by Region USD Million (2021-2026)
  • Table 145. Metformin Drugs Extended Release , by Region USD Million (2021-2026)
  • Table 146. Metformin Drugs: by Form(USD Million)
  • Table 147. Metformin Drugs Tablets , by Region USD Million (2021-2026)
  • Table 148. Metformin Drugs Capsules , by Region USD Million (2021-2026)
  • Table 149. Metformin Drugs Liquid , by Region USD Million (2021-2026)
  • Table 150. Metformin Drugs: by Distribution Channel(USD Million)
  • Table 151. Metformin Drugs Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 152. Metformin Drugs Hospitals Dispensaries , by Region USD Million (2021-2026)
  • Table 153. Metformin Drugs Third Party Websites , by Region USD Million (2021-2026)
  • Table 154. South America Metformin Drugs, by Country USD Million (2021-2026)
  • Table 155. South America Metformin Drugs, by Type USD Million (2021-2026)
  • Table 156. South America Metformin Drugs, by Category USD Million (2021-2026)
  • Table 157. South America Metformin Drugs, by Form USD Million (2021-2026)
  • Table 158. South America Metformin Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 159. Brazil Metformin Drugs, by Type USD Million (2021-2026)
  • Table 160. Brazil Metformin Drugs, by Category USD Million (2021-2026)
  • Table 161. Brazil Metformin Drugs, by Form USD Million (2021-2026)
  • Table 162. Brazil Metformin Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 163. Argentina Metformin Drugs, by Type USD Million (2021-2026)
  • Table 164. Argentina Metformin Drugs, by Category USD Million (2021-2026)
  • Table 165. Argentina Metformin Drugs, by Form USD Million (2021-2026)
  • Table 166. Argentina Metformin Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 167. Rest of South America Metformin Drugs, by Type USD Million (2021-2026)
  • Table 168. Rest of South America Metformin Drugs, by Category USD Million (2021-2026)
  • Table 169. Rest of South America Metformin Drugs, by Form USD Million (2021-2026)
  • Table 170. Rest of South America Metformin Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 171. Asia Pacific Metformin Drugs, by Country USD Million (2021-2026)
  • Table 172. Asia Pacific Metformin Drugs, by Type USD Million (2021-2026)
  • Table 173. Asia Pacific Metformin Drugs, by Category USD Million (2021-2026)
  • Table 174. Asia Pacific Metformin Drugs, by Form USD Million (2021-2026)
  • Table 175. Asia Pacific Metformin Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 176. China Metformin Drugs, by Type USD Million (2021-2026)
  • Table 177. China Metformin Drugs, by Category USD Million (2021-2026)
  • Table 178. China Metformin Drugs, by Form USD Million (2021-2026)
  • Table 179. China Metformin Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 180. Japan Metformin Drugs, by Type USD Million (2021-2026)
  • Table 181. Japan Metformin Drugs, by Category USD Million (2021-2026)
  • Table 182. Japan Metformin Drugs, by Form USD Million (2021-2026)
  • Table 183. Japan Metformin Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 184. India Metformin Drugs, by Type USD Million (2021-2026)
  • Table 185. India Metformin Drugs, by Category USD Million (2021-2026)
  • Table 186. India Metformin Drugs, by Form USD Million (2021-2026)
  • Table 187. India Metformin Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 188. South Korea Metformin Drugs, by Type USD Million (2021-2026)
  • Table 189. South Korea Metformin Drugs, by Category USD Million (2021-2026)
  • Table 190. South Korea Metformin Drugs, by Form USD Million (2021-2026)
  • Table 191. South Korea Metformin Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 192. Taiwan Metformin Drugs, by Type USD Million (2021-2026)
  • Table 193. Taiwan Metformin Drugs, by Category USD Million (2021-2026)
  • Table 194. Taiwan Metformin Drugs, by Form USD Million (2021-2026)
  • Table 195. Taiwan Metformin Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 196. Australia Metformin Drugs, by Type USD Million (2021-2026)
  • Table 197. Australia Metformin Drugs, by Category USD Million (2021-2026)
  • Table 198. Australia Metformin Drugs, by Form USD Million (2021-2026)
  • Table 199. Australia Metformin Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 200. Rest of Asia-Pacific Metformin Drugs, by Type USD Million (2021-2026)
  • Table 201. Rest of Asia-Pacific Metformin Drugs, by Category USD Million (2021-2026)
  • Table 202. Rest of Asia-Pacific Metformin Drugs, by Form USD Million (2021-2026)
  • Table 203. Rest of Asia-Pacific Metformin Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 204. Europe Metformin Drugs, by Country USD Million (2021-2026)
  • Table 205. Europe Metformin Drugs, by Type USD Million (2021-2026)
  • Table 206. Europe Metformin Drugs, by Category USD Million (2021-2026)
  • Table 207. Europe Metformin Drugs, by Form USD Million (2021-2026)
  • Table 208. Europe Metformin Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 209. Germany Metformin Drugs, by Type USD Million (2021-2026)
  • Table 210. Germany Metformin Drugs, by Category USD Million (2021-2026)
  • Table 211. Germany Metformin Drugs, by Form USD Million (2021-2026)
  • Table 212. Germany Metformin Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 213. France Metformin Drugs, by Type USD Million (2021-2026)
  • Table 214. France Metformin Drugs, by Category USD Million (2021-2026)
  • Table 215. France Metformin Drugs, by Form USD Million (2021-2026)
  • Table 216. France Metformin Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 217. Italy Metformin Drugs, by Type USD Million (2021-2026)
  • Table 218. Italy Metformin Drugs, by Category USD Million (2021-2026)
  • Table 219. Italy Metformin Drugs, by Form USD Million (2021-2026)
  • Table 220. Italy Metformin Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 221. United Kingdom Metformin Drugs, by Type USD Million (2021-2026)
  • Table 222. United Kingdom Metformin Drugs, by Category USD Million (2021-2026)
  • Table 223. United Kingdom Metformin Drugs, by Form USD Million (2021-2026)
  • Table 224. United Kingdom Metformin Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 225. Netherlands Metformin Drugs, by Type USD Million (2021-2026)
  • Table 226. Netherlands Metformin Drugs, by Category USD Million (2021-2026)
  • Table 227. Netherlands Metformin Drugs, by Form USD Million (2021-2026)
  • Table 228. Netherlands Metformin Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 229. Rest of Europe Metformin Drugs, by Type USD Million (2021-2026)
  • Table 230. Rest of Europe Metformin Drugs, by Category USD Million (2021-2026)
  • Table 231. Rest of Europe Metformin Drugs, by Form USD Million (2021-2026)
  • Table 232. Rest of Europe Metformin Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 233. MEA Metformin Drugs, by Country USD Million (2021-2026)
  • Table 234. MEA Metformin Drugs, by Type USD Million (2021-2026)
  • Table 235. MEA Metformin Drugs, by Category USD Million (2021-2026)
  • Table 236. MEA Metformin Drugs, by Form USD Million (2021-2026)
  • Table 237. MEA Metformin Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 238. Middle East Metformin Drugs, by Type USD Million (2021-2026)
  • Table 239. Middle East Metformin Drugs, by Category USD Million (2021-2026)
  • Table 240. Middle East Metformin Drugs, by Form USD Million (2021-2026)
  • Table 241. Middle East Metformin Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 242. Africa Metformin Drugs, by Type USD Million (2021-2026)
  • Table 243. Africa Metformin Drugs, by Category USD Million (2021-2026)
  • Table 244. Africa Metformin Drugs, by Form USD Million (2021-2026)
  • Table 245. Africa Metformin Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 246. North America Metformin Drugs, by Country USD Million (2021-2026)
  • Table 247. North America Metformin Drugs, by Type USD Million (2021-2026)
  • Table 248. North America Metformin Drugs, by Category USD Million (2021-2026)
  • Table 249. North America Metformin Drugs, by Form USD Million (2021-2026)
  • Table 250. North America Metformin Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 251. United States Metformin Drugs, by Type USD Million (2021-2026)
  • Table 252. United States Metformin Drugs, by Category USD Million (2021-2026)
  • Table 253. United States Metformin Drugs, by Form USD Million (2021-2026)
  • Table 254. United States Metformin Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 255. Canada Metformin Drugs, by Type USD Million (2021-2026)
  • Table 256. Canada Metformin Drugs, by Category USD Million (2021-2026)
  • Table 257. Canada Metformin Drugs, by Form USD Million (2021-2026)
  • Table 258. Canada Metformin Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 259. Mexico Metformin Drugs, by Type USD Million (2021-2026)
  • Table 260. Mexico Metformin Drugs, by Category USD Million (2021-2026)
  • Table 261. Mexico Metformin Drugs, by Form USD Million (2021-2026)
  • Table 262. Mexico Metformin Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 263. Research Programs/Design for This Report
  • Table 264. Key Data Information from Secondary Sources
  • Table 265. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Metformin Drugs: by Type USD Million (2015-2020)
  • Figure 5. Global Metformin Drugs: by Category USD Million (2015-2020)
  • Figure 6. Global Metformin Drugs: by Form USD Million (2015-2020)
  • Figure 7. Global Metformin Drugs: by Distribution Channel USD Million (2015-2020)
  • Figure 8. South America Metformin Drugs Share (%), by Country
  • Figure 9. Asia Pacific Metformin Drugs Share (%), by Country
  • Figure 10. Europe Metformin Drugs Share (%), by Country
  • Figure 11. MEA Metformin Drugs Share (%), by Country
  • Figure 12. North America Metformin Drugs Share (%), by Country
  • Figure 13. Global Metformin Drugs share by Players 2020 (%)
  • Figure 14. Global Metformin Drugs share by Players (Top 3) 2020(%)
  • Figure 15. Global Metformin Drugs share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Bristol-Mayers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 18. Bristol-Mayers Squibb (United States) Revenue: by Geography 2020
  • Figure 19. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 20. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2020
  • Figure 21. Harman Finochem (India) Revenue, Net Income and Gross profit
  • Figure 22. Harman Finochem (India) Revenue: by Geography 2020
  • Figure 23. Vistin Pharma (Norway) Revenue, Net Income and Gross profit
  • Figure 24. Vistin Pharma (Norway) Revenue: by Geography 2020
  • Figure 25. China Res Double-Crane (China) Revenue, Net Income and Gross profit
  • Figure 26. China Res Double-Crane (China) Revenue: by Geography 2020
  • Figure 27. Farmhispania Group (Spain) Revenue, Net Income and Gross profit
  • Figure 28. Farmhispania Group (Spain) Revenue: by Geography 2020
  • Figure 29. Shijiazhuang Polee Pharmaceutical (China) Revenue, Net Income and Gross profit
  • Figure 30. Shijiazhuang Polee Pharmaceutical (China) Revenue: by Geography 2020
  • Figure 31. Merck Sante S.A.S. (France) Revenue, Net Income and Gross profit
  • Figure 32. Merck Sante S.A.S. (France) Revenue: by Geography 2020
  • Figure 33. Aarti Drugs Limited (India) Revenue, Net Income and Gross profit
  • Figure 34. Aarti Drugs Limited (India) Revenue: by Geography 2020
  • Figure 35. Taj Pharmaceuticals Limited (India) Revenue, Net Income and Gross profit
  • Figure 36. Taj Pharmaceuticals Limited (India) Revenue: by Geography 2020
  • Figure 37. Global Metformin Drugs: by Type USD Million (2021-2026)
  • Figure 38. Global Metformin Drugs: by Category USD Million (2021-2026)
  • Figure 39. Global Metformin Drugs: by Form USD Million (2021-2026)
  • Figure 40. Global Metformin Drugs: by Distribution Channel USD Million (2021-2026)
  • Figure 41. South America Metformin Drugs Share (%), by Country
  • Figure 42. Asia Pacific Metformin Drugs Share (%), by Country
  • Figure 43. Europe Metformin Drugs Share (%), by Country
  • Figure 44. MEA Metformin Drugs Share (%), by Country
  • Figure 45. North America Metformin Drugs Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Bristol-Mayers Squibb (United States)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Harman Finochem (India)
  • Vistin Pharma (Norway)
  • China Res Double-Crane (China)
  • Farmhispania Group (Spain)
  • Shijiazhuang Polee Pharmaceutical (China)
  • Merck Sante S.A.S. (France)
  • Aarti Drugs Limited (India)
  • Taj Pharmaceuticals Limited (India)
Additional players considered in the study are as follows:
Wanbury Limited (India) , Granules India Limited (India) , Keyuan Pharmaceutical (China) , Fukang Pharmaceutical (China)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation